Yong-Jin Park, Joon Ho Choi, Hyunjong Lee, Seung Hwan Moon, Inki Lee, Joohee Lee, Jang Yoo, Joon Young Choi
{"title":"18F-FDOPA PET/CT在肿瘤学中的应用：韩国核医学学会程序指南。","authors":"Yong-Jin Park, Joon Ho Choi, Hyunjong Lee, Seung Hwan Moon, Inki Lee, Joohee Lee, Jang Yoo, Joon Young Choi","doi":"10.1007/s13139-024-00899-6","DOIUrl":null,"url":null,"abstract":"<p><p>This guideline outlines the use of 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on international standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effective application of 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowledge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 1","pages":"41-49"},"PeriodicalIF":1.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772901/pdf/","citationCount":"0","resultStr":"{\"title\":\"<sup>18</sup>F-FDOPA PET/CT in Oncology: Procedural Guideline by the Korean Society of Nuclear Medicine.\",\"authors\":\"Yong-Jin Park, Joon Ho Choi, Hyunjong Lee, Seung Hwan Moon, Inki Lee, Joohee Lee, Jang Yoo, Joon Young Choi\",\"doi\":\"10.1007/s13139-024-00899-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This guideline outlines the use of 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on international standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effective application of 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowledge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.</p>\",\"PeriodicalId\":19384,\"journal\":{\"name\":\"Nuclear Medicine and Molecular Imaging\",\"volume\":\"59 1\",\"pages\":\"41-49\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772901/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear Medicine and Molecular Imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13139-024-00899-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine and Molecular Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13139-024-00899-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
本指南概述了3,4-二羟基-6- 18f -氟- l -苯丙氨酸正电子发射断层扫描/计算机断层扫描在神经内分泌肿瘤、脑肿瘤和其他肿瘤条件的诊断和管理中的使用。它提供了关于患者准备、成像程序和结果解释的详细建议。该指南以国际标准为基础，并适应当地临床实践，强调安全性、质量控制以及3,4-二羟基-6- 18f -氟- l -苯丙氨酸正电子发射断层扫描/计算机断层扫描对胰岛素瘤、嗜铬细胞瘤和甲状腺髓样癌等各种肿瘤的有效应用。它还讨论了卡比多巴用药前、禁食方案和最佳成像技术的使用。其目的是协助核医学专业人员提供精确的诊断，改善患者的治疗效果，并适应不断发展的医学知识和技术。这个全面的文件作为一个实用的资源，以提高准确性，质量和安全性的3,4-二羟基-6- 18f -氟- l -苯丙氨酸正电子发射断层扫描/计算机断层扫描在肿瘤学。
18F-FDOPA PET/CT in Oncology: Procedural Guideline by the Korean Society of Nuclear Medicine.
This guideline outlines the use of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on international standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effective application of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowledge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.
期刊介绍：
Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging) is an official journal of the Korean Society of Nuclear Medicine, which bimonthly publishes papers on February, April, June, August, October, and December about nuclear medicine and related sciences such as radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. The journal specially welcomes works of artificial intelligence applied to nuclear medicine. The journal will also welcome original works relating to molecular imaging research such as the development of molecular imaging probes, reporter imaging assays, imaging cell trafficking, imaging endo(exo)genous gene expression, and imaging signal transduction. Nucl Med Mol Imaging publishes the following types of papers: original articles, reviews, case reports, editorials, interesting images, and letters to the editor.
The Korean Society of Nuclear Medicine (KSNM)
KSNM is a scientific and professional organization founded in 1961 and a member of the Korean Academy of Medical Sciences of the Korean Medical Association which was established by The Medical Services Law. The aims of KSNM are the promotion of nuclear medicine and cooperation of each member. The business of KSNM includes holding academic meetings and symposia, the publication of journals and books, planning and research of promoting science and health, and training and qualification of nuclear medicine specialists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
